|
|
Article: CYTRX CLINICAL TRIAL OF ARIMOCLOMOL FOR ALS SHOWS PROMISE.
- Article from:
- Biotech Business
- Article date:
- August 1, 2007
CopyrightCOPYRIGHT 2007 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CytRx Corporation (NASDAQ:CYTR), Los Angeles, Calif., a biopharmaceutical company engaged in the development and commercialization of human therapeutics, has announced promising data from the six-month, open-label extension of its completed Phase IIa clinical trial with arimoclomol in ALS volunteers. While the clinical trial was not placebo- controlled, arimoclomol at a 100 mg dose three times daily appeared to be safe and well-tolerated throughout the six- month period. Further, the rate of decline of several key disease symptom indicators, including the Revised ALS Functional Rating Scale (ALSFRS-R), which measures overall functional capacity, and vital capacity, which ...